Teams of researchers measured the antibody and cellular responses generated by a messenger RNA vaccine in patients with systemic lupus (LS). This work shows that vaccination is both well tolerated and effective, even against worrying variants. The factors associated with a ...
As the effects of the COVID-19 crisis continue to make themselves felt, how do we answer the many health questions raised by citizens and make space for scientific information that is useful in everyday life? More motivated than ever to provide robust ...
Les manifestations cliniques développées à la suite d’une infection par le SARS-CoV-2 sont variables chez les individus, et les mécanismes pouvant expliquer cette variabilité restent encore méconnus. La muqueuse nasale étant un des premiers points d’entrée du virus, des chercheurs de l’Institut ...
Des chercheurs et chercheuses ont mené des travaux sur la capacité de la mémoire immunitaire générée après vaccination ARNm à reconnaître et neutraliser les variants du SARS-CoV-2. ...
Since the pandemic began, many studies have tried to explain what differentiates the immune response of people with severe forms of COVID-19 resulting in death from that of other patients. In a new study, researchers from Inserm and Sorbonne Université at the ...
The Discovery clinical trial was initially launched in France by Inserm in March 2020, to evaluate several possible treatments for COVID-19. Its European expansion was made possible by the EU-RESPONSE project, funded by the European Commission. Interim analysis of the trial data ...
Press release
14.12.2021
Press release
21.10.2021
06.12.2021
09.12.2021